Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer

Colloids and Surfaces B: Biointerfaces

Volumn 94, Issue , 2012, Pages 274-280

  Saxena, Vipin ^a   Naguib, Youssef ^a   Hussain, M Delwar ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

17 AAG; Breast cancer; Folic acid; Nanoparticles; Polylactide co glycolide

Indexed keywords

17-AAG; BREAST CANCER; CELLULAR UPTAKE; CLINICAL USE; CONTROLLED RELEASE; DRUG LOADING; FOLATE RECEPTOR; FOLIC ACIDS; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEPATOTOXICITY; HUMAN BREAST CANCER CELLS; IN-VITRO; INTRACELLULAR UPTAKE; LOW WATER; NANOMETER SIZE; NON-TARGETED; POLY LACTIDE-CO-GLYCOLIDE; POLYMERIC NANOPARTICLES; TARGETED DELIVERY; TARGETED NANOPARTICLE;

CYTOTOXICITY; DISEASES; LOADING; ORGANIC ACIDS; POLYETHYLENE GLYCOLS;

NANOPARTICLES;

COUMARIN 6; COUMARIN DERIVATIVE; FOLATE RECEPTOR; NANOCONJUGATE; POLYGLACTIN MACROGOL FOLIC ACID NANOCONJUGATE; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RESPONSE; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; KINETICS; LACTAMS, MACROCYCLIC; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; SOLUBILITY;

EID: 84859164996     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.02.001     Document Type: Article

References (44)

1. Whitesell L., Lindquist S.L. Nat. Rev. Cancer 2005, 5:761-772.
2. Bagatell R., Whitesell L. Mol. Cancer Ther. 2004, 3:1021-1030.
3. Neckers L., Lee Y.S. Nature 2003, 425:357-359.
4. Neckers L., Ivy S.P. Curr. Opin. Oncol. 2003, 15:419-424.
5. Xiao L., Lu X., Ruden D.M. Mini Rev. Med. Chem. 2006, 6:1137-1143.
6. Gimenez Ortiz A., Montalar Salcedo J. Clin. Transl. Oncol. 2010, 12:166-173.
7. Biamonte M.A., Van de Water R., Arndt J.W., Scannevin R.H., Perret D., Lee W.C. J. Med. Chem. 2010, 53:3-17.
8. Porter J.R., Ge J., Lee J., Normant E., West K. Curr. Top. Med. Chem. 2009, 9:1386-1418.
9. Xiong M.P., Yanez J.A., Kwon G.S., Davies N.M., Forrest M.L. J. Pharm. Sci. 2009, 98:1577-1586.
10. Burris H.A., Berman D., Murthy B., Jones S. Cancer Chemother. Pharmacol. 2011, 67:1045-1054.
11. Richardson P.G., Chanan-Khan A.A., Alsina M., Albitar M., Berman D., Messina M., Mitsiades C.S., Anderson K.C. Br. J. Haematol. 2010, 150:438-445.
12. Chandran T., Katragadda U., Teng Q., Tan C. Int. J. Pharm. 2010, 392:170-177.
13. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. Nature 2003, 425:407-410.
14. Onyuksel H., Mohanty P.S., Rubinstein I. Int. J. Pharm. 2009, 365:157-161.
15. Rowinsky E.K., Donehower R.C. N. Engl. J. Med. 1995, 332:1004-1014.
16. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Eur. J. Cancer 2001, 37:1590-1598.
17. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. J. Clin. Oncol. 2005, 23:1078-1087.
18. Shin H.C., Alani A.W., Rao D.A., Rockich N.C., Kwon G.S. J. Control Release 2009, 140:294-300.
19. Won Y.W., Yoon S.M., Sonn C.H., Lee K.M., Kim Y.H. ACS Nano 2011, 5:3839-3848.
20. Maeda H. Adv. Enzyme Regul. 2001, 41:189-207.
21. Larson N., Greish K., Bauer H., Maeda H., Ghandehari H. Int. J. Pharm. 2011, 420:111-117.
22. Leamon C.P., Reddy J.A. Adv. Drug Deliv. Rev. 2004, 56:1127-1141.
23. Sudimack J., Lee R.J. Adv. Drug Deliv. Rev. 2000, 41:147-162.
24. Low P.S., Kularatne S.A. Curr. Opin. Chem. Biol. 2009, 13:256-262.
25. Wang S., Low P.S. J. Control Release 1998, 53:39-48.
26. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J., Low P.S., Knutson K.L., Hartmann L.C. Gynecol. Oncol. 2008, 108:619-626.
27. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J., Varghese B., Hillman D., Oberg A.L., Low P.S. Int. J. Cancer 2007, 121:938-942.
28. Esmaeili F., Ghahremani M.H., Ostad S.N., Atyabi F., Seyedabadi M., Malekshahi M.R., Amini M., Dinarvand R. J. Drug Target 2008, 16:415-423.
29. Ebrahimnejad P., Dinarvand R., Sajadi A., Jaafari M.R., Nomani A.R., Azizi E., Rad-Malekshahi M., Atyabi F. Nanomedicine 2010, 6:478-485.
30. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. J. Pharm. Sci. 2000, 89:1452-1464.
31. Stella B., Marsaud V., Arpicco S., Geraud G., Cattel L., Couvreur P., Renoir J.M. J. Drug Target 2007, 15:146-153.
32. Chen J., Li S., Shen Q., He H., Zhang Y. Drug Dev. Ind. Pharm. 2011, 37:1339-1346.
33. Xu P., Van Kirk E.A., Li S., Murdoch W.J., Ren J., Hussain M.D., Radosz M., Shen Y. Colloids Surf. B: Biointerfaces 2006, 48:50-57.
34. Yoo H.S., Park T.G. J. Control Release 2004, 96:273-283.
35. Yoon J.J., Nam Y.S., Kim J.H., Park T.G. Biotechnol. Bioeng. 2002, 78:1-10.
36. Stephenson S.M., Low P.S., Lee R.J. Methods Enzymol. 2004, 387:33-50.
37. Jeong Y.I., Song J.G., Kang S.S., Ryu H.H., Lee Y.H., Choi C., Shin B.A., Kim K.K., Ahn K.Y., Jung S. Int. J. Pharm. 2003, 259:79-91.
38. Mao S., Shi Y., Li L., Xu J., Schaper A., Kissel T. Eur. J. Pharm. Biopharm. 2008, 68:214-223.
39. Beirowski J., Inghelbrecht S., Arien A., Gieseler H. J. Pharm. Sci. 2011, 100:1958-1968.
40. Hirsjarvi S., Peltonen L., Hirvonen J. AAPS PharmSciTech 2009, 10:488-494.
41. Kamiya S., Kurita T., Miyagishima A., Itai S., Arakawa M. Eur. J. Pharm. Biopharm. 2010, 74:461-466.
42. Zhang Z., Huey Lee S., Feng S.S. Biomaterials 2007, 28:1889-1899.
43. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. FASEB J. 2002, 16:1217-1226.
44. Gabizon A.A. Cancer Res. 1992, 52:891-896.